$3.86
0.31[8.73%]
At close: Apr 26
$3.86
0[0.00%]
After Hours: 4:00PM EDT
Summit Therapeutics
(NASDAQ:SMMT)Summit Therapeutics Stock (NASDAQ:SMMT), Analyst Ratings, Price Targets, Predictions
Summit Therapeutics Inc has a consensus price target of $8, established from looking at the 1 latest analyst ratings. The last 1 analyst ratings were released from Stifel on March 26, 2024. With an average price target of $8 between Stifel, there's an implied 107.25% upside for Summit Therapeutics Inc from these 1 analyst ratings.
Analyst Firms Making Recommendations1
Stifel
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Summit Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/26/2024 | SMMT | Buy Now | Summit Therapeutics | $3.86 | 107.25% | Stifel | Bradley Canino | → $8 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Summit Therapeutics (SMMT)?
The latest price target for Summit Therapeutics (NASDAQ: SMMT) was reported by Stifel on March 26, 2024. The analyst firm set a price target for $8.00 expecting SMMT to rise to within 12 months (a possible 107.25% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Summit Therapeutics (SMMT)?
The latest analyst rating for Summit Therapeutics (NASDAQ: SMMT) was provided by Stifel, and Summit Therapeutics initiated their buy rating.
When was the last upgrade for Summit Therapeutics (SMMT)?
There is no last upgrade for Summit Therapeutics.
When was the last downgrade for Summit Therapeutics (SMMT)?
There is no last downgrade for Summit Therapeutics.
When is the next analyst rating going to be posted or updated for Summit Therapeutics (SMMT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Summit Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Summit Therapeutics was filed on March 26, 2024 so you should expect the next rating to be made available sometime around March 26, 2025.
Is the Analyst Rating Summit Therapeutics (SMMT) correct?
While ratings are subjective and will change, the latest Summit Therapeutics (SMMT) rating was a initiated with a price target of $0.00 to $8.00. The current price Summit Therapeutics (SMMT) is trading at is $3.86, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.